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Abstract
Objective: To investigate the impact of whole body C5a receptor (C5aR) deficiency on energy metabolism and fat storage.
Design: Male wildtype (WT) and C5aR knockout (C5aRKO) mice were fed a low fat (CHOW) or a high fat high sucrose diet-
induced obesity (DIO) diet for 14 weeks. Body weight and food intake were measured weekly. Indirect calorimetry, dietary
fatload clearance, insulin and glucose tolerance tests were also evaluated. Liver, muscle and adipose tissue mRNA gene
expression were measured by RT-PCR.
Results: At week one and 12, C5aRKO mice on DIO had increased oxygen consumption. After 12 weeks, although food
intake was comparable, C5aRKO mice had lower body weight (27% CHOW, 212% DIO) as well as smaller gonadal (238%
CHOW, 236% DIO) and inguinal (229% CHOW, 230% DIO) fat pads than their WT counterparts. Conversely, in WT mice,
C5aR was upregulated in DIO vs CHOW diets in gonadal adipose tissue, muscle and liver, while C5L2 mRNA expression was
lower in C5aRKO on both diet. Furthermore, blood analysis showed lower plasma triglyceride and non-esterified fatty acid
levels in both C5aRKO groups, with faster postprandial triglyceride clearance after a fatload. Additionally, C5aRKO mice
showed lower CD36 expression in gonadal and muscle on both diets, while DGAT1 expression was higher in gonadal
(CHOW) and liver (CHOW and DIO) and PPARc was increased in muscle and liver.
Conclusion: These observations point towards a role (either direct or indirect) for C5aR in energy expenditure and fat
storage, suggesting a dual role for C5aR in metabolism as well as in immunity.
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Introduction
It is now widely accepted that obesity is regarded as a state of
chronic low-level inflammation, with increased circulating levels of
inflammatory markers. Further, white adipose tissue (WAT) is a
key endocrine and secretory organ, which produces and releases a
wide range of proteins and factors designated adipokines, a
number of which are involved in inflammation and the
inflammatory response, including leptin, adiponectin, interleukin
1b (IL-1b), IL-6 and monocyte chemotactic protein-1 (MCP-1).
The extensive crosstalk between WAT and other tissues, coupled
to increased production of inflammation-related adipokines in
obesity, is considered important in the development of obesity-
associated diseases, predominantly type II diabetes and metabolic
syndrome [1]. Tumor Necrosis Factor a (TNFa) is a well-known
example of this dual role, as it was originally named ‘cachectin’
due to its proinflammatory effects which are also associated with
metabolic effects such as cachexia, weight loss, tissue fatty acid
release and insulin resistance [2]. Likewise, IL-6 is an immune-
modulating cytokine that influences insulin resistance in peripheral
tissues; while toll-like receptors (TLRs), important in immune
function, also influence metabolism via fatty acid interactions [3].
The complement system proteins, such as C3 and its cleavage
products, C3a and C3adesArg (acylation stimulating protein,
ASP), as well as factor B, adipsin (factor D) and others, are
additional examples of immune system proteins present in the
WAT environment, further expanding this concept of a dual
immune-metabolic role in adipose tissue [4,5]. In fact, this
association between the complement system and WAT has a
storied past, as shown by the early discovery that acquired
lipodystrophy was found to coincide with C3 hypocomplemente-
mia [6], even prior to the first descriptions of familial C3
deficiency presenting with partial lipodystrophy [7]. ASP/
C3adesArg has been shown to stimulate triglyceride synthesis in
adipocytes by promoting fatty acid uptake and glucose transport
while C3
2/2 mice, which are obligately deficient in ASP, as well
as factor B
2/2 and adipsin/factor D
2/2 mice, all demonstrate
both immune and metabolic alterations, including altered energy
metabolism and fat clearance [8,9]. Furthermore, it has recently
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e62531been shown by Gauvreau et al that properdin, a C3 convertase
stabilizer, also plays a dual role as demonstrated by decreased
energy expenditure and altered postprandial lipid clearance in
properdin
2/2 mice [10].
C3a receptor (C3aR), C5a receptor (C5aR) and C5L2 (G-
protein receptor 77, GPR77) constitute a trio of related receptors
which variously bind the anaphylatoxins C3a, C3adesArg/ASP,
C5a and C5adesArg, all cleavage products of complement
pathway activation [11]. While C3aR binds only C3a, but not
the desarginated peptide C3adesArg/ASP, C5aR binds both C5a
and (to a lesser extent) C5adesArg. C5L2 ligand binding remains
controversial: while both C5a and C5adesArg bind with high
affinity, the functional outcome (signalling vs. decoy receptor)
remains unclear; further some [12,13] but not all [14,15] studies
report low affinity binding of C3adesArg/ASP and C3a to C5L2.
While all three receptors appear to have well-defined immune-
related roles, the potential duality of these receptors in adipose
tissue and in immune-metabolic function is only beginning to be
considered [16]. In this respect, several studies have demonstrated
a role for C3a and C3aR in asthma, sepsis, liver regeneration, as
well as autoimmune encephalomyelitis [17,18], and only just
recently, a role for C3aR in insulin resistance and adipose tissue
macrophage infiltration has been proposed [19]. Similarly, studies
with C5L2
2/2 mice have demonstrated roles for C5L2 in
inflammation [20,21] and sepsis [22] as well as insulin resistance
and lipid metabolism [23,24].
C5a has multiple immune functions, including stimulation of
histamine secretion in mast cells, chemotactic activity, and
facilitation of phagocyte mobilization. However, in addition to
myeloid cells and tissues, C5aR is also widely expressed in
connective tissue, circulatory system, kidney, liver, lung and skin
[25] and is recognized as a pleiotropic factor with a range of
biological functions such as contraction of smooth muscle and
increasing capillary vessel permeability [26,27,25]. C5aR deficient
mice show alterations in many of the disease processes that involve
C5a, such as mucosal defence, rheumatoid arthritis, contact
sensitivity, glomerulonephritis, pulmonary hypersensitivity, peri-
tonitis, and sepsis [25,28]. While C5a-C5aR often plays a
protective role, excess generation can lead to negative conse-
quences and antagonists have been developed for use in disease
models [25,28].
C5a and its receptor are also present in the central nervous
system [29] and it has been reported that C5a stimulates food
intake after central administration [30]. Further, a very recent
study in rats by Lim et al [31], demonstrated that C3a and C5a
could both affect adipocyte nutrient storage, and in vivo adminis-
tration of specific C3aR and C5aR antagonists reduced fat tissue
size when coupled with a high fat diet. Given the dual immune-
metabolic functions of many adipokines, cytokines and comple-
ment system proteins, including C3aR and C5L2, we hypothesized
that C5aR
2/2 (C5aRKO) mice would also demonstrate a duality
in C5aR function, either through a direct effect or an indirect
effect (consequent to changes in immune function due to the
absence of C5aR). The aim of the present study was to investigate
energy homeostasis, particularly energy expenditure, growth,
physical activity, food intake, substrate utilization and storage,
and gene expression in relation to adipose, muscle and liver tissues
in C5aR deficient mice under normal low fat chow (CHOW) and
high fat diet-induced obesity (DIO) conditions.
Materials and Methods
Ethical Statement
All protocols were conducted in accordance with the CACC
guidelines and were pre-approved by the Laval University Animal
Care Committee (Quebec, Canada) and the Laval Hospital
Research Institute (CRIUCPQ, Quebec, Canada) committee. All
research protocols followed these guidelines and all efforts were
made to minimize suffering. At protocol initiation, 8–9 week-old
mice were housed individually in a sterile barrier facility with a
fade-in/fade-out 12 h light: 12 h dark cycle within the animal
facility. The cage also included enrichment toys such as cotton
batting and plastic tubes. Mice were euthanized at 22–23 weeks of
age after 14 weeks of diet through anesthesia followed by cervical
dislocation prior to dissection.
Mice
The C5aR deficient homozygous mice were kindly provided by
John Lambris (University of Pennsylvania School of Medicine,
Table 1. Body and tissue weights, food intake and plasma parameters in wildtype and C5aR knockout mice.
WT CHOW C5aRKO CHOW WT DIO C5aRKO DIO
Initial body weight (g) 23.160.4 22.660.4 23.860.5 23.160.5
Cummulative food intake (kcal) 1247628 1280625 1505629
a 1513653
b
Glucose (mmol/L) 8.9161.10 9.3660.81 10.6360.75 9.8760.77
Insulin (ng/ml) 0.3960.03 0.3560.04 0.5360.05
a 0.4860.07
Leptin (ng/ml) 5.4660.28 5.3960.75 18.3963.37
a 15.8763.23
b
TG (mmol/L) 0.4160.02 0.3060.02* 0.5460.04
a 0.3760.03***
NEFA (mmol/L) 0.6260.04 0.4960.03* 0.8060.05
a 0.6260.05*
Cholesterol (mmol/L) 0.4860.01 0.4260.03 0.6960.04
a 0.5760.03*
TISSUE WEIGHTS
Muscle (g) 0.3260.01 0.3160.01 0.3360.01 0.3160.01
Liver (g) 1.1660.03 1.0360.05* 1.0860.04 1.0360.05
Body and tissue weights, food intake and plasma triglyceride (TG), non-esterified fatty acids (NEFA) and cholesterol were measured in wildtype (WT) and C5aRKO on
chow and high fat high sucrose diet-induced obesity (DIO) diet for n=10–14 per group. Results are expressed as means 6 SEM, and statistical differences were
evaluated by ANOVA followed by Bonferroni post-test, where *P,0.05 and ***P,0.0001 vs WT on their respective diet, or for DIO vs CHOW where ‘‘a’’ indicates P,0.05
for WT DIO vs WT CHOW and ‘‘b’’ indicates P,0.05 for C5aRKO DIO vs C5aRKO CHOW.
doi:10.1371/journal.pone.0062531.t001
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PA) in collaboration with Craig Gerard (Pulmonary Division,
Department of Pediatrics, Children’s Hospital, Department of
Medicine, Harvard Medical School, Boston, Massachusetts) via
Jackson Laboratories (The Jackson Laboratory, Bar Harbor, ME).
Detailed methodology for development of these transgenic mice
has been previously published elsewhere [32]. Homozygous
breeding in our internal colony generated C5aRKO littermates.
C57BL6 mice (WT), purchased from Jackson Laboratories were
bred in our animal facility and matched for age, sex, and starting
body weight with the C5aRKO cohort. At protocol initiation, 8–9
week-old mice were housed individually in a sterile barrier facility
with a fade-in/fade-out 12 h light: 12 h dark cycle within the
animal facility. The cage also included enrichment toys such as
cotton batting and plastic tubes. Mice were placed on low fat chow
diet (CHOW: 18% kcal fat, 58% complex carbohydrate (no
sucrose), #2918; Harlan Laboratories, Montreal, Canada) or a
high fat high sucrose diet-induced obesity diet (DIO: 45% kcal fat,
35% carbohydrate of which half (17% total) is sucrose, #D12451;
Research Diets Inc., New Brunswick, NJ, USA) and were
euthanized at 22–23 weeks of age after 14 weeks of diet through
anesthesia followed by cervical dislocation prior to dissection.
Mice were evenly distributed in separate subset studies for food
intake (n=14 per group) and for metabolic chamber analysis
(n=8 per group). Body weight and food intake were measured
twice per week for 14 weeks. Calorimetric measurements were
taken at week 1 and 12. Oxygen consumption (VO2) and carbon
dioxide production (VCO2) were measured over a 48-hour period
in an open circuit system following 48 hours equilibration as
previously described [33]. VO2 and VCO2 were calculated as
mL/kg/min and RQ (respiratory quotient) was taken as the ratio
of VCO2/VO2.
At termination of protocol, mice were fasted for 6 h, euthanized
through anesthesia followed by cervical dislocation, blood was
collected through cardiac puncture, and tissues were collected and
immediately frozen in liquid nitrogen, then transferred to 280uC.
All protocols were conducted in accordance with the CACC
guidelines and approved by the Laval University Animal Care
Committee (Quebec, Canada) and the Laval Hospital Research
Institute (CRIUCPQ, Quebec, Canada) committee.
Plasma Analysis
Blood was collected after 6 h fasting. Blood glucose levels were
measured using a glucometer with strips (LifeScan, Milpitas, CA,
USA). Plasma triglyceride (TG), non-esterified fatty acid (NEFA)
and cholesterol were measured by colorimetric enzymatic kits as
follows: plasma TG (Roche Diagnostics, Indianapolis, IN, USA),
NEFA and cholesterol (Wako Chemicals, Osaka, Japan). Mouse
Figure 1. Oxygen consumption and locomotor activity. (A and B): Oxygen consumption after diet treatment for one week (A) and 12 weeks
(B), evaluated over a 48 hour period for wildtype (WT, open circles) and C5aRKO mice (solid circles) on a high fat high sucrose diet-induced obesity
(DIO) diet. (C): Respiration quotient (RQ) for the same 48 hour period for WT and C5aRKO mice on CHOW or DIO diet. (D): Total walking distance over
the 48-hour period for WT and C5aRKO mice on CHOW or DIO diet. Results are presented as means 6 SEM of n=8 mice per group. For calorimetry
results, ‘‘dark cycle’’ indicates the active period. Data were analysed by 2-way RM-ANOVA (A and B) and by ANOVA followed by t-test (C and D), where
*P,0.05 for C5aRKO vs WT on their respective diets, unless otherwise indicated.
doi:10.1371/journal.pone.0062531.g001
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St-Charles, MO, USA). Plasma insulin was measured using the
Ultra Sensitive Mouse Insulin ELISA kit from Crystal Chem Inc.
(Downers Grove, IL, USA). Plasma C5a was measured using a
sandwich ELISA (DuoSet ELISA, cat DY2150) from R&D
Systems (Minneapolis, MN, USA). A mouse complement C3
ELISA kit (Kamiya Biomedical, Seattle, WA, USA) was used to
measure total C3, including native and breakdown products, and
was used according to the manufacturer’s instructions with
calculation by linear regression against a standard curve.
Indirect Calorimetry
For indirect calorimetry, mice were placed in metabolic
chambers for measurement of oxygen consumption (VO2), carbon
dioxide production (VCO2), and respiratory quotient (RQ) over a
48-h period in an open-circuit system with an S-3A1 oxygen
analyzer and a CD-3A carbon dioxide analyzer, both from
Applied Electrochemistry (Pittsburgh, PA, USA). VO2 and VCO2
were calculated as millilitres per minute, and respiratory quotient
(RQ) was calculated as the ratio of VCO2/VO2. The metabolic
chambers from AccuScan Instruments (Columbus, OH, USA)
consisted of rectangular, air-proof cages (30630620 cm), linked to
an open-circuit, flow-through calorimetric device connected to a
computer-controlled system of data acquisition. In these cham-
bers, it was also possible to estimate locomotor activity (via a grid
of invisible infrared light beams, XY movement corresponding to
distance, XYZ corresponding to total activity), while analysing
indirect calorimetry.
Intragastric Fat Meal Administration, Insulin and Glucose
Tolerance Tests
Oral fat load tests, consisting of olive oil (13 ml/g of body weight
with 100 ml of air above the oil), were administered by intragastric
gavage feeding tube following an overnight fast after 12 weeks of
diet (n=5 mice per group). Tail vein blood samples were taken at
0, 2, 3, 4, and 6 h after administration of the fat load. All blood
samples were collected in 2% EDTA, separated by centrifugation
at 5,000 g for 5 min, and stored at –20uC.
At week 13 of the diet regimen, an insulin tolerance test (ITT)
was performed following a 6 h fast (n=7 mice per group). Blood
samples were taken at 0, 15, 30, 60 and 90 min after an intra-
peritoneal insulin injection (0.5 mU/g of body weight, Humulin,
Lilly). Glucose was measured using a glucometer, as described
above.
In a separate group of mice, at week 13, glucose tolerance tests
(GTT) were conducted following an overnight fast (n=7 mice per
group). An intraperitoneal glucose injection (2 mg/g of body
weight) was given, and blood samples were taken at 0, 15, 30, 60,
Figure 2. Altered body weight and fat pad weight in C5aR deficient mice. (A): Growth curve during diet treatment with CHOW or high fat
high sucrose diet-induced obesity (DIO) diet in wildtype (WT) and C5aRKO mice (B): Final body weight for WT and C5aRKO mice on CHOW or DIO
diet. (C and D): Tissue weights of gonadal (C) and inguinal (D) fat pads of WT and C5aRKO mice at the end of the protocol. Results are presented as
means 6 SEM of n=12–14 mice per group, data are analysed by 2 way ANOVA (A), or ANOVA followed by t-test (B–D) where *P,0.05, **P,0.01 and
***P,0.001 and comparisons refer to C5aRKO vs WT on their respective diets, unless otherwise indicated.
doi:10.1371/journal.pone.0062531.g002
C5aR and Energy Metabolism
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e62531and 90 min from the tail vein. Glucose was measured using a
glucometer, as described above.
MCP-1, KC, C3 and ASP Secretion in Adipose Tissue
Gonadal adipose tissues from WT and C5aR KO (n=5–8)
CHOW and DIO treated mice were collected, minced, and
aliquots were incubated overnight in serum-free medium
(DMEM/F12) and used for determination of C3 (as indicated
above) and mouse ASP/C3adesArg. ASP was measured using a
sandwich ELISA as previously described (Gao 2010). Note, the
antibody used in this ELISA is specific for a neoepitope exposed in
mouse C3a and its desArginated form (ASP/C3adesArg), but does
not cross-react with the native protein C3. Mouse ASP (C3a)
ELISA reagents were from BD Pharmingen (Franklin Lakes, NJ,
USA). In separate experiments, adipose tissue aliquots were
treated with C5a (VWR, Mississauga, ON, Canada), LPS (Sigma-
Aldrich, Oakville, ON, Canada), and LPS+C5a for 24 hr. The
media was then collected and used in ELISA assays for
determination of mouse KC/CXCL1 (Cat # DY453) and mouse
MCP-1/CCL2/JE (Cat # DY479) from R&D Systems (Minne-
apolis, MN, USA).
RNA Extraction and Real Time qPCR Analysis
RNA was extracted from quadriceps muscle, liver and gonadal
fat pad of WT and C5aRKO mice, using RNeasy Plus Universal
Mini Kit. For muscle and liver, 0.4 mg of total RNA and for
gonadal fat, 1 ug of total RNA were retrotranscribed by RT
2 First
Strand kit (Qiagen Inc., Mississauga, ON, Canada). Genomic
DNA contamination was eliminated by DNase treatment included
in RT
2 First Strand kit. RT
2 SYBRH Green qPCR Master Mix
(Qiagen Inc., Mississauga, ON, Canada) was used and a 3-step
PCR was performed using CFX96
TM Real-Time PCR Detection
System (Bio-Rad Laboratories, Mississauga, ON, Canada). C5aR
primers were obtained from Qiagen (Gaithersburg, MD). Mouse
qPrimerDepot resource site (mouseprimerdepot.nci.nih.gov) was
used to identify specific primers for C5L2, DGAT1, DGAT2, CD36,
LPL, FAS, PPARG, F4/80, CD11c and Eef2 (as housekeeping gene).
Primers were ordered from Alpha-DNA (Montreal, Canada). All
sequences for the primers used are listed in Table S1. As the
efficiency of the housekeeping gene Eef2 was similar to that of the
genes of interest, relative gene expression was calculated and
corrected using Eef2 using the delta-delta-Ct method.
Statistical Analysis
Graphical results are presented as mean 6 SEM. Each group
contains results from a mean of 8–11 mice per group. Groups
were compared by t-tests, one-way or two-way ANOVA or by
two-way repeated measures ANOVA (RM-ANOVA) followed by
Bonferroni post-test, as appropriate for the data, using Prism 5.0
software (GraphPad Software Inc., La Jolla, CA, USA). Statistical
significance was set at P,0.05, where NS indicates not significant.
Results
Effect of C5aR Deficiency on Food Intake
Since it has previously been demonstrated that central
administration of C5a stimulates food intake [30], food consump-
tion as well as other energy-related parameters were first evaluated
in wildtype and C5aR knockout mice on both low fat (CHOW)
and high fat (DIO) diets. Importantly, to avoid dominant peer
influence, mice were housed individually; food intake was
measured twice per week. As shown in Table 1, there was no
difference in total calories ingested between KO and WT on either
CHOW or DIO diets, although there was the expected increase in
caloric intake within each genotype on the DIO diet.
Figure 3. C5aR and C5L2 expression in adipose, muscle and liver of mice. C5aR mRNA expression for WT CHOW (open bars) and WT diet-
induced obesity (DIO) (checkered bars) for (A) gonadal adipose tissue, (B) quadriceps muscle, and (C) liver were measured. C5L2 mRNA expression for
WT CHOW (open bars), WT DIO (checkered bars), KO CHOW (black bars) and KO DIO (striped bars) for (D) gonadal adipose tissue, (E) quadriceps
muscle, and (F) liver were evaluated. Results are expressed as means 6 SEM; n=9–12 per group. Statistical differences were determined by t-test, for
C5aRKO vs WT on their respective diets where *P,0.05, **P,0.001 and ***P,0.0001.
doi:10.1371/journal.pone.0062531.g003
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Energy expenditure was measured with indirect calorimetry,
using several parameters. After one week of DIO diet, as shown in
Fig. 1A, O2 consumption was higher in C5aRKO mice compared
to WT mice (p,0.001, 2way ANOVA). Over the 48-h period, this
increase was present in both the dark cycle, when mice are known
to initiate eating, and in the light (sleeping) cycle. There was no
significant difference between KO and WT mice on CHOW diet
(data not shown). Interestingly, the same results were observed
after 12 weeks of the DIO diet, as shown in Fig. 1B, O2
consumption was increased over a 48-h period in C5aRKO mice
compared to WT mice. Analysis of RQ, which is indicative of
relative energy substrate usage (glucose vs. fatty acid), indicates
that C5aRKO mice receiving a CHOW diet had a preference for
glucose oxidation, as indicated by higher RQ compared with WT
mice (Fig. 1C). On a DIO diet, RQ decreases, indicative of greater
fat oxidation relative to glucose (Fig. 1C). Physical activity,
evaluated as two components: cumulative walking distance and
total activity, was also monitored during the time in the
calorimetric chambers. Cumulative walking distance represents
movement within the x-axis direction, whereas total activity
accounts for movement within all three axes. Over the 48-h time
period, C5aRKO mice walked less vs WT mice (Fig. 1D)
regardless of CHOW or DIO diet, although there was no
difference in total physical activity (data not shown).
Effect of C5aR Deficiency on Diet-induced Obesity
At initiation of the dietary protocol, mice were matched for age
and initial body weight (Table 1 and Fig. 2A). Over the diet
protocol, the C5aRKO mice gained on average 2–4 g (7–12%)
less weight than their WT counterparts during the 14 weeks of the
study (Fig. 2A and B). This resistance to weight gain observed in
the C5aRKO was reflected by smaller gonadal (236% to 238%)
Figure 4. Metabolic response to glucose and insulin tolerance tests and postprandial lipid clearance in C5aRKO mice. (A): Plasma
glucose levels following an intraperitoneal injection of glucose in WT (open symbols) and C5aRKO (solid symbols) mice after 13 weeks of low fat
CHOW or diet-induced obesity (DIO) diet for n=6–7 mice per group. (B): Plasma glucose levels following an intra-peritoneal injection of insulin in WT
(open symbols) and C5aRKO (solid symbols) mice after 13 weeks of CHOW or DIO diet for n=6–7 mice per group. Triglyceride (TG; C and D)
postprandial lipid clearance following an oral fat load for WT (open symbols), C5aRKO (solid symbols) mice on CHOW (C) and diet-induced obesity
(DIO) (D) diets for n=5 mice per group. Results are presented as means 6 SEM; data are analysed by 2-way RM-ANOVA followed by Bonferroni post-
test for individual time point differences, where *P,0.05, and **P,0.001 for KO vs. WT and by t-test for the incremental area-under-the curve (IAUC),
where *P,0.05 vs WT on the same diet.
doi:10.1371/journal.pone.0062531.g004
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PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e62531Figure 5. C3 and C5a plasma level and mRNA expression in muscle and liver of genes implicated in substrate utilization. Plasma
levels of C3 (A) and C5a (B) in WT and C5aRKO on chow and DIO diet for n=8–12 per group. Gene expression in quadriceps muscle tissue (C) and
liver (D) for fatty acid transporter (CD36), fatty acid synthase (FAS), lipoprotein lipase (LPL), diacylglycerolacyltransferase-1 (DGAT1),
diacylglycerolacyltransferase-2 (DGAT2) and peroxisome-proliferator activated receptor gamma (PPARG) were measured in WT CHOW diet (open
bars), C5aRKO CHOW (solid bars), WT diet-induced obesity (DIO) diet (checkered bars) and C5aRKO DIO (striped bars) for n=6–12 per group. Results
are expressed as means 6 SEM; statistical differences were determined by t-test, where *P,0.05 and**P,0.001 and ***P,0.0001 for C5aRKO vs WT
on the same diet, unless otherwise indicated.
doi:10.1371/journal.pone.0062531.g005
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slight decrease in final liver weight on CHOW diet when
compared to WT control (Table 1). On the other hand, while
there were DIO diet-induced changes in leptin, an adipokine
strongly reflective of adipose tissue mass, there was no difference
between C5aRKO and WT mice (Table 1) in spite of differences
in adipose tissue mass.
Figure 6. Evaluation of adipose tissue immune and metabolic function in C5aRKO mice. Gene expression for immune factors CD11c (A)
and F4/80 (B) and for lipid-related factors fatty acid transporter (CD36), fatty acid synthase (FAS), lipoprotein lipase (LPL), diacylglycerolacyltransferase-
1( DGAT1), diacylglycerolacyltransferase-2 (DGAT2) and peroxisome-proliferator activated receptor gamma (PPARG) (G) were evaluated in WT CHOW
diet (open bars), C5aRKO CHOW (solid bars), WT DIO diet (checkered bars) and C5aRKO DIO (striped bars) in gonadal adipose tissue, where n=6–
12 per group. MCP-1 (C) and KC (D) secretion were measured in ex vivo adipose tissue in WT (white bars) and C5aRKO (diagonally striped bars) mice
following overnight (24h) treatment with C5a (50 ng/mL), LPS, or both vs control (CTL) where n=8–10 per group. Ex vivo C3 secretion (E) and ASP
production (F) were measured in media from adipose tissue of WT CHOW diet, C5aRKO CHOW, WT DIO and C5aRKO DIO incubated for 24 h. Results
are expressed as means 6 SEM; statistical differences were determined by ANOVA followed by Bonferroni post-test, where *P,0.05, **P,0.001 and
***P,0.0001 vs CTL (C, D) or vs WT on their respective diet (A,B,E-G) unless otherwise indicated.
doi:10.1371/journal.pone.0062531.g006
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Although C5a-C5aR functions have been largely investigated
from the perspective of an immune response, based on the
detected differences in energy expenditure, physical activity and
adipose tissue weights, the results suggested that C5aR might play
a role (either direct or indirect) in adipose, muscle and liver
metabolism. Accordingly, C5aR gene expression was evaluated in
the WT mice fed a CHOW or DIO diet. Expression was identified
in gonadal adipose, muscle and liver tissues (Fig 3 A, B and C),
where DIO diet fed WT mice showed a higher expression of C5aR
vs CHOW diet fed WT mice for all three tissues. In addition,
C5L2 expression was also evaluated in WT and C5aRKO mice on
both diets (Fig 3 D-F). We observed a striking lowering of C5L2
expression in the muscle of C5aRKO mice compared to their WT
counterpart (Fig 3E), with a smaller effect in adipose tissue (3D),
but no difference in C5L2 expression in liver tissue (Fig 3F).
Metabolic Insulin and Glucose Response of C5aRKO Mice
Insulin-related metabolism was further evaluated in detail under
fasting conditions, as well as following insulin sensitivity tests.
Fasting blood glucose levels were similar in all 4 groups and while
fasting blood insulin levels were identical between C5aRKO and
the WT mice on the same diet, the WT mice on the DIO diet had
increased insulin levels as compared to their CHOW counterparts
(Table 1). At week 13, both glucose and insulin tolerance tests were
administered to assess insulin sensitivity on both CHOW and DIO
diets (Fig. 4 A and B). In spite of the decreased body and adipose
tissue weights, blood glucose excursion in both groups of
C5aRKO mice was not different during the glucose tolerance
test (GTT) (Fig. 4A). Additionally, no significant difference in the
insulin-induced decrease in blood glucose during the insulin
tolerance test (ITT) was detected in the C5aRKO mice on either
diet compared with WT mice (Fig. 4B). Furthermore, there was no
difference in IRS1 expression in adipose, skeletal muscle and liver
tissues (data not shown).
C5aRKO Lipid Metabolism
In addition to assessment of adipose tissue depot weights (Fig 2),
in vivo lipid metabolism and several lipid parameters were also
analyzed. At the end of the diet protocol, fasting plasma
triglyceride, NEFA and total cholesterol were measured. As
indicated in Table 1, C5aRKO mice on the CHOW diet showed
lower plasma levels of triglyceride and NEFA as compared to WT.
Similarly on DIO diet, C5aRKO mice had lower plasma levels of
triglyceride, NEFA and total cholesterol vs WT counterparts.
Although there was no difference between WT and C5aRKO
mice in postprandial fat tolerance clearance on a CHOW diet,
C5aRKO mice demonstrated a significantly more rapid clearance
on the DIO diet (Fig 4C and D). To evaluate the mechanism for
these changes in both fasting and postprandial lipids in C5arKO
mice, related plasma variables, as well as muscle, liver and adipose
tissue parameters were evaluated.
While there was no change in circulating ASP (data not shown),
C3 plasma levels were lower in C5aRKO mice when compared to
their WT counterparts (Fig 5A), while C5a plasma level was
influenced by the DIO diet only in the WT group (Fig. 5 B).
Additionally, mRNA expression of key parameters in lipid
metabolism was evaluated in skeletal muscle and liver. No
differences were seen in LPL, FAS, DGAT1 and DGAT2 in muscle.
There were however marked differences identified in skeletal
muscle such as higher PPARG expression and lower CD36
expression in C5aRKO mice on the CHOW and DIO diet
(Fig. 5C). In liver, there were no differences in CD36, FAS and i.
However, there was an increase in PPARG (Fig. 5D). In liver,
DGAT2 is more closely associated with esterification of de novo
synthesized fatty acids, whereas DGAT1 is more associated with
esterification of exogenously derived fatty acids [34] and
interestingly, C5aRKO mice demonstrated higher levels of
DGAT1, with reciprocal decreases in DGAT2 expression (Fig 5D).
C5aRKO Adipose Tissue Function
As noted above, C5aRKO mice have smaller adipose tissue
depots (Fig 2C and D) and, coupled to the higher C5aR expression
level with DIO diet (Fig 3A), this suggests potential alterations in
adipose immune function and macrophage infiltration. Accord-
ingly, macrophage markers F4/80 and CD11c were evaluated in
adipose tissue. DIO treatment resulted in higher F4/80 (Fig 6A)
and CD11c (Fig 6B) expression when compared to the CHOW for
both the WT and the C5aRKO, however, the C5aRKO mice on
DIO had lower expression vs the WT on DIO. The immune
responses of adipose tissue to LPS and C5a were evaluated. In in
WT mice, LPS stimulation resulted in an increase in MCP-1
(Fig 6C) and KC (Fig 6D) secretion. In C5aRKO, there is a similar
LPS stimulation of both MCP-1 and KC secretion (Fig 6C and D).
In adipose tissue from WT mice, while addition of C5a alone had
no effect on MCP-1 and KC secretion, C5a has a synergistic effect
to LPS. By contrast, in C5aRKO mice there is no C5a effect, and
no synergy to the LPS effect.
As ASP and its precursor C3 are both immune complement
factors produced by adipose tissue, which affect adipose tissue
energy storage, we evaluated secretion in WT and C5aRKO mice.
As shown in figure 6E and 6F, C5aRKO mice on CHOW diet
produced significantly less C3 and ASP, although DIO diet
resulted in increases in both WT and C5aRKO mice (with a trend
to less in the C5aRKO mice).
Finally, there were changes in mRNA expression in gonadal
adipose tissue of C5aRKO, as compared to WT controls. As
showed in figure 6G, we observed lower mRNA expression of
CD36 in C5aR mice on both diets and higher DGAT1 expression
in adipose tissue of C5aRKO mice on the CHOW diet (Fig 6G).
Discussion
In the present study, the effects of C5aR deficiency on energy
homeostasis, particularly energy expenditure, substrate utilization
and storage as well as energy balance were evaluated. While it was
previously shown that C5a stimulates food intake after central
administration [30] our study showed no effects of C5aR
deficiency in mice on food consumption whether on a CHOW
or DIO diet.
On the other hand, this study demonstrates metabolic effects of
a disrupted C5a-C5aR pathway: more specifically, C5aRKO mice
have decreased body and adipose tissue weights and decreased fat
storage whether on a CHOW or DIO diet. This is associated, for
the DIO treated C5aRKO mice, with no change in food intake,
but increased energy expenditure which could be centrally
mediated. In C5aRKO mice, in spite of the decreased fat mass,
glucose clearance and insulin tolerance are comparable to WT
littermates. On the other hand, both groups of C5aRKO mice
displayed lower lipid factors, including lower plasma triglyceride
and NEFA and, on a DIO diet, lower cholesterol as well as a faster
lipid clearance following a postprandial fat tolerance test. Lastly,
our assessment of C5aR in WT mice, convey that there is a direct
impact of the diet on C5aR, since we observed increased C5aR
mRNA expression in the gonadal adipose tissue, muscle and liver
tissues of the WT mice on the DIO diet. Altogether, these results
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towards usage, potentially in such tissues as muscle and liver,
although the direct impact of C5aR on metabolic pathways in cell
studies remains to be evaluated.
Crosstalk between the immune system and adipose tissue is now
widely accepted, and the integration of nutrient- and pathogen-
sensing pathways goes far back in evolution and involves many
factors including insulin, PPAR, mTOR, ER stress, TLRs, as
elegantly reviewed by Hotamisligil [35]. However, the involve-
ment of complement activation in adipose tissue changes is still
relatively unexplored [4,5,16]. Complement proteins such as
complement C3 [36,37], adipsin [38], C3adesArg/acylation
stimulating protein [39], properdin [10], factor H [40], C5L2
[23,24] and C3aR [19] have all been implicated in lipid and
glucose metabolism. The present effects on metabolism in the
C5arKO mice may be the consequence of a direct role of C5aR in
energy/lipid metabolism, as C5aR is expressed in adipose, muscle,
liver, brain and other tissues involved in nutrient sensing and lipid
metabolism, however indirect effects due to changes in immune
responses cannot be ruled out.
While C5aR binds both C5a and C5adesArg, C5L2 ligand
binding remains controversial: both C5a and C5adesArg bind with
high affinity, yet the functional outcome (signalling vs decoy
receptor) remains unclear; and some [12,13] but not all [14,41,15]
studies report low affinity binding of C3adesArg/ASP and C3a to
C5L2. Further, expression of C5L2 and C5aR can be tissue-specific
and regulated differentially based on cell treatments or disease
conditions as shown elsewhere [42,43], and as shown in the
present study. As well, co-localization has been demonstrated in
human neutrophils, suggesting a mutual cooperation or regulation
between the two receptors [44]. Further, we have recently
demonstrated that C5L2-C5aR heterodimerize, and are internal-
ized upon stimulation by ligands [45]. With regards to this, it is
tempting to speculate on three models of action to explain the
modified lipid metabolism observed in the present C5aRKO mice
study.
Firstly, C5a or C5adesArg interaction with C5aR might have
direct effects in adipose, muscle or liver (metabolic and/or
immune), and the absence of C5aR could cause pathway
disruption which leads to decreased adipose tissue mass and
decreased levels of lipemic factors. C5a has been shown to have
central effects on food intake [30], although whether this is
mediated through C5aR or an alternate receptor (C5L2) is
unknown. A recent study by Lim et al [31], demonstrating direct
effects of C5a on glucose uptake and triglyceride synthesis in 3T3
adipocytes, effects that were blocked with the use of a specific
C5aR antagonist, supports this interpretation.
A second mechanism might be that, in the absence of C5aR,
there is increased interaction of C5a with C5L2 that then leads to
these effects on adipose tissue/lipid metabolism. Enhancement of
C5a interaction with C5L2 when C5aR is deficient or blocked
with antagonists has been proposed as the mechanism for C5a
effects on sepsis [46]. Evaluation of potential direct effects of C5a
on adipocytes from C5aRKO mice in future studies will answer
these questions.
A third mechanism would be an indirect effect of C5aR
deficiency, in which the increased availability of C5a and
C5adesArg, due to the absence of C5aR, interferes with ASP
interaction with C5L2 pathway leading to the metabolic effects
demonstrated. As ASP has been shown to stimulate triglyceride
synthesis in adipocytes, an effect that is absent in adipose tissue
from C5L2KO mice, this would support this mechanism. Further,
a recent study demonstrating that both ASP/C3adesArg and C5a
stimulate C5L2-C5aR heterodimerization in adipocytes, leading
to activation of intracellular signalling pathways is supportive of
this [45].
However, we cannot exclude that all three mechanisms may be
involved in the phenotype identified, and we speculate that the
changes in adipose tissue function could be a consequence of (i) the
absence of C5a-C5aR interaction (which removes the effect of C5a
on lipid storage) and (ii) increased C5a interaction with C5L2 (a
consequence of higher plasma C5a, lower adipose tissue C5L2 and
lower production of ASP as shown in the present study) which
leads to (iii) interference of ASP-C5L2 interaction, and prevention
of ASP stimulation of lipid storage On the other hand, the absence
of C5aR in adipose tissue did not prevent (i) DIO-induced increase
in macrophage infiltration (based on F4/80 and CD11c expres-
sion) or (ii) LPS-induced increases in MCP-1 and KC secretion,
although the C5a synergy was lost in C5aRKO. Overall, these
results suggest that, at least in adipose tissue, the absence of C5aR
induces metabolic changes with minor changes in immune
response.
The recent paper by Lim et al is complementary and supportive
of the present study, demonstrating that in vivo inhibition of the
C5a-C5aR pathway, using receptor-selective antagonists of C5aR,
improved the presentation of metabolic syndrome in diet-induced
obese rats, with less increase in body weight, visceral fat and
adiposity as well as showing improvements in glucose and insulin
resistance [31]. Furthermore, they showed using in vitro studies on
3T3-L1 adipocytes, the involvement of the C5a-C5aR pathway in
promoting energy conservation by increasing glucose and fatty
acid uptake while inhibiting cAMP signalling and lipolysis [31].
Their results, coupled with the present study indicating higher
energy expenditure, lower adipose tissue, and enhanced fat
clearance suggest that blockade of C5aR, as targeted in the
development of antagonists (review: [25]), may be beneficial in
unexpected ways.
Conclusion
The present study adds to and extends the accumulating data
that the complement immune system is involved in many facets of
adipose tissue metabolism and establishes a foundation that C5aR,
in addition to its effect on the immune system, plays a role in
energy metabolism and especially on lipid metabolism.
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